June 5, 2018 A 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months with chemotherapy, which is currently the standard of care, in Persephone, a phase III randomized clinical trial of women with HER2-positive early-stage breast cancer. The shorter duration was associated with lower rates of discontinuation due...
Pro zobrazení tohoto obsahu je třeba být přihlášen.